Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, on 27 march provided a corporate update and announced operational and financial results for the fourth quarter and full year ended December 31, 2013. Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) shares after opening at $28.25 moved to $28.25 on last trade day and at the end of the day closed at $26.51. Company price to sales ratio in past twelve months was calculated as 74.73 and price to cash ratio as 8.61. Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) showed a negative weekly performance of -23.00%.
MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company developing, manufacturing and commercializing innovative therapies to address unmet needs in severe burn and wound management, on 25 march announced the closing of its initial public offering of 5,750,000 ordinary shares at a price to the public of $14.00 per share. Mediwound Ltd (NASDAQ:MDWD) shares fell -1.94% in last trading session and ended the day on $14.13. MDWD return on equity ratio is recorded as 74.90% and its return on assets is -30.80%.
On March 26, 2014, Ruthigen, Inc. (NASDAQ:RTGN) filed a restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the Company’s initial public offering of its securities. Ruthigen Inc. (NASDAQ:RTGN) shares moved down -1.32% in last trading session and was closed at $6.75, while trading in range of $6.51 – $6.85. Ruthigen Inc. (NASDAQ:RTGN) year to date (YTD) performance is -6.90%.
Recro Pharma Inc. (NASDAQ:REPH) after its first few weeks of public trading has posted 21 percent depreciation in its market value. Recro Pharma Inc. (NASDAQ:REPH) weekly performance is -14.88%. On last trading day company shares ended up $6.98. Recro Pharma Inc. (NASDAQ:REPH) distance from 50-day simple moving average (SMA50) is -13.72%. Analysts mean target price for the company is $26.00.